Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor evolution. Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Autores principales: Ge, Jennifer Y., Shu, Shaokun, Kwon, Mijung, Jovanović, Bojana, Murphy, Katherine, Gulvady, Anushree, Fassl, Anne, Trinh, Anne, Kuang, Yanan, Heavey, Grace A., Luoma, Adrienne, Paweletz, Cloud, Thorner, Aaron R., Wucherpfennig, Kai W., Qi, Jun, Brown, Myles, Sicinski, Piotr, McDonald, Thomas O., Pellman, David, Michor, Franziska, Polyak, Kornelia
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214447/
https://ncbi.nlm.nih.gov/pubmed/32393766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-16170-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares